Bioresorbable Scaffolds - Global Strategic Business Report

  • ID: 2531222
  • Report
  • Region: Global
  • 126 Pages
  • Global Industry Analysts, Inc
1 of 4

FEATURED COMPANIES

  • Abbott Laboratories (USA)
  • REVA Medical, Inc. (USA)
  • MORE

The report provides separate comprehensive analytics for the US, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Market data and analytics are derived from primary and secondary research.

This report analyzes the worldwide markets for Bioresorbable Scaffolds in US$ Thousand.

Company profiles are primarily based on public domain information including company URLs.

The report profiles 17 companies including many key and niche players such as:

- Abbott Laboratories
- Amaranth Medical, Inc.
- Arterial Remodeling Technologies SA
- BIOTRONIK SE & Co. KG
- Elixir Medical Corp.
- Kyoto Medical Planning Co., Ltd.

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abbott Laboratories (USA)
  • REVA Medical, Inc. (USA)
  • MORE

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW
BioResorbable Scaffolds/Stents
A Prelude
Clinical Characteristics of Various Coronary Stents
Bioresorbable Vascular Scaffolds: Advantages and Challenges
Evolution of Coronory Stents
Global Coronory Stents Market
A Few Key Facts
Bioresorbable Stents
A Revolutionary Technology, Riddled with Controversies
Abbott Stops Sales of the Once Promising ‘Absorb’ Bioresorbable Stents due to Adverse Events
Impact of Abbott’s Withdrawal of Absorb on the Bioresorbable Stent Industry
Challenges in Next-generation BVS Development
Other Available Bioresorbable Scaffolds Exhibit Potential
Approved Bioresorbable Scaffolds
Magmaris Exhibits Stability and Safety with Lack of Scaffold Thrombosis Occurrence
Fantom from REVA Medical
DESolve from Elixir Medical
ART from Arterial Remodeling Technologies
Bioresorbable Scaffolds in Pipeline
Current & Future Analysis
Developing Countries
Hot Spots for Growth

2. ABSORB III TRIALS
CHANGING THE FACE OF THE BIORESORBABLE STENTS INDUSTRY
Absorb Bioresorbable Scaffold/Stent Trials
Adverse Outcomes after Two Years of Placement
The ABSORB III Trials
Performance of Absorb in Smaller Vessels

3. GROWTH DRIVERS & MARKET TRENDS
Global Menace of Coronary Artery Disease (CAD)
A Major Growth Driver
Table 1: Global Annual Medical Cost of CVD in the United States: 2015-2030 (includes corresponding Graph/Chart)
Table 2: Fatalities by Heart Conditions
Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others (includes corresponding Graph/Chart)
Table 3: Top 10 Causes of Death Globally: 2015 (includes corresponding Graph/Chart)
Table 4: Top 10 Causes of Death in Low-Income Economies: 2015 (includes corresponding Graph/Chart)
Table 5: Top 10 Causes of Death in Lower-Middle-Income Economies: 2015 (includes corresponding Graph/Chart)
Table 6: Top 10 Causes of Death in Upper-Middle-Income Economies: 2015 (includes corresponding Graph/Chart)
Table 7: Top 10 Causes of Death in High-Income Economies: 2015 (includes corresponding Graph/Chart)
Ageing Demographics and Longer Life Expectancy Bolsters Market Growth
Table 8: Global Population Statistics for the 65+ Age Group (2015) (includes corresponding Graph/Chart)
Table 9: Life Expectancy for Select Countries in Number of Years: 2015E (includes corresponding Graph/Chart)
Rising Middle Class Population Aids Growth
Table 10: Global Middle Class Population (in Millions) by Geographic Region: 2010, 2020P & 2030P (includes corresponding Graph/Chart)
Rising Healthcare Expenditure: Opportunities in Store
Table 11: Top Countries with the Highest Per Capita Healthcare Spending (2014) (includes corresponding Graph/Chart)
Table 12: Healthcare Spending as % of GDP by Geographic Region: 2016 (includes corresponding Graph/Chart)
Risk of CAD in Obesity Offers Prospects for Coronary Stenting
Table 13: Global Obesity Epidemic: Percentage of Overweight, Obese, and Severely Obese Adults for 2014 & 2025 (includes corresponding Graph/Chart)
Table 14: Severely Obese Population (in Thousands) Worldwide by Country: 2014 & 2025 (includes corresponding Graph/Chart)
Diabetics at Higher Risk of Heart Diseases
Table 15: Diabetes Prevalence Worldwide by Region: Number of Adults (20-79 Years) with Diabetes in 2015 and 2040 (includes corresponding Graph/Chart)
Table 16: Global Prevalence (%) of Diabetes in Adults (20-79) by Region: 2015 & 2040 (includes corresponding Graph/Chart)
Table 17: Global Prevalence of Diabetes by Gender (2015 & 2040): Number of Adults Diagnosed with Diabetes (in Million) for Men and Women (includes corresponding Graph/Chart)
Table 18: Top 10 Countries with Highest Number of Adults Diagnosed with Diabetes (in Million) for 2015 & 2040 (includes corresponding Graph/Chart)
The Hypertension-Cholesterol Link to Drive Demand
Table 19: Worldwide Prevalence of Hypertension (BP>=140 OR DBP>=90) (age-standardized estimate) among Male and Female (2014): Breakdown by Select Countries
Spurt in Medical Tourism Offers Growth Opportunities
Metal Bioresorbable scaffolds Exhibit Improved Performance Compared to Polymer Stents
Metal Stents Vis-à-vis Other Stents
Alternative Therapies/Devices: Threats to Coronary Stents
Cell Transplantation
A Threat to Coronary Stents

4. PIPELINE ANALYSIS
Falcon from Abbott
Fortitude, Aptitude, and Magnitude from Amaranth
Renuvia from Boston Scientific
Ideal from Xenogenics
MeRes from Meril
Mirage from Manli Cardiology
Xinsorb from HuaAn Biotechnology
Firesorb from MicroPort
Unity from QualiMed

5. REGULATORY FRAMEWORK
The United States
Europe
Australia

6. PRODUCT OVERVIEW

7. RECENT INDUSTRY ACTIVITY
The DGCI Warns Against the Use of Absorb in 2.5 mm or Narrower Blood Vessels
Akesys and Elixir Medical Completes Successful Implantation of PRAVA™ for Peripheral Vascular Disease
Elixir Medical Showcases DESolve CX and AMITY® at EuroPCR 2016
Micell Technologies Announces Commercialization of MiStent SES® in Europe

8. CLINICAL TRIALS AND PRODUCT APPROVALS
Elixir Medical Confirms Excellent 5-Year Clinical Data for DESolve®
Amaranth Medical Announces Nine-month Follow-up RENASCENT-II Study Results of the APTITUDE®
Abbott's Absorb™ Receives Approval as the Japan’s First Fully Dissolving Heart Stent
Amaranth Medical Initiates Clinical Study for MAGNITUDE™ Sirolimus-Eluting Bioresorbable Scaffold
Abbott's Absorb™ Receives Health Canada Approval
BIOTRONIK Obtains CE Mark Approval for Magmaris, the First Magnesium Bioresorbable Scaffold
Abbott's Absorb™ Receives FDA Approval
US FDA Approves Boston Scientific’s SYNERGY™ BP-DES
Abbott Receives CE Mark for Absorb GT1™
ART Receives CE Mark Clearance for its Pure Bioresorbable Scaffold

9. FOCUS ON SELECT GLOBAL PLAYERS
Abbott Laboratories (USA)
Amaranth Medical, Inc. (USA)
Arterial Remodeling Technologies SA (France)
BIOTRONIK SE & Co. KG (Germany)
Elixir Medical Corp. (USA)
Kyoto Medical Planning Co., Ltd. (Japan)
REVA Medical, Inc. (USA)

10. GLOBAL MARKET PERSPECTIVE
Table 20: World Current and Future Analysis for Bioresorbable Scaffolds by Geographic Region
US, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Thousands for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 21: World 9-Year Perspective for Bioresorbable Scaffolds by Geographic Region
Percentage Breakdown of Dollar Sales for US, Europe, Asia-Pacific, and Rest of World Markets for Years 2017 and 2024 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES
A.Market Analysis
Abbott’s Decision to End Absorb Sales Brings the US Bioresorbable Scaffolds Market to a Standstill
Increasing Incidence of CAD to Drive the Need for More Research into Bioresorbable Stents
Rising CVD Incidence
A Major Growth Driver
Table 22: Cardiovascular Disease Incidence in the US by Gender & Age Group (per 1,000 Adults) (includes corresponding Graph/Chart)
Table 23: Leading Causes of CVD Fatalities in the US: Percentage Breakdown of Mortality for Coronary Heart Disease, HBP, Heart Failure, Stroke, and Others (includes corresponding Graph/Chart)
Ageing Population
A Vital Demography
Table 24: Aging Population in the US (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)
Clinical Trials and Product Approvals
Strategic Corporate Development
Select Key Players
B.Market Analytics
Table 25: The US Current and Future Analysis for Bioresorbable Scaffolds Market Analyzed with Annual Sales in US$ Thousands for Years 2016 through 2024

2. EUROPE
A.Market Analysis
The Largest Market for Bioresorbable Scaffolds Globally
Abbott Restricts Availability of Absorb
Growth Drivers
Cardiovascular Disease in Europe
A Perspective
Europe
A Highly Diverse Market
Absorbable Stents & the Controversies Surrounding Them
Ageing Population Boosts Demand for Biodegradable Stents
Table 26: European Country-wise Statistics of 65+ Population as % of Total Population: As on January 1, 2015 (includes corresponding Graph/Chart)
Strategic Corporate Developments
Product Approvals
Key Players
B.Market Analytics
Table 27: European Current and Future Analysis for Bioresorbable Scaffolds Market Analyzed with Annual Sales in US$ Thousands for Years 2016 through 2024 (includes corresponding Graph/Chart)

3. ASIA-PACIFIC
A.Market Analysis
The Fastest Growing Market for Bioresorbable Scaffolds
Growth Drivers
Aging Populace
Potential Opportunities
Table 28: Over 65 Years Individuals as % of the Total Population in Select Asian Countries (includes corresponding Graph/Chart)
Asia-Pacific
A Price Sensitive Market
India & China Offer Significant Growth Opportunities
Table 29: China and India Lead Global Population (2015): Table Depicting China and India’s Huge Population Vis-a-Vis Other Countries’ Population (in Millions) by Age Group (includes corresponding Graph/Chart)
Focus on Select Markets
Australia
India
Japan
China
Strategic Corporate Development
Kyoto Medical Planning Co., Ltd. (Japan)
A Key Player
B.Market Analytics
Table 30: Asia-Pacific Current and Future Analysis for Bioresorbable Scaffolds Market Analyzed with Annual Sales in US$ Thousands for Years 2016 through 2024 (includes corresponding Graph/Chart)

4. REST OF WORLD
A.Market Analysis
Product Approvals
B.Market Analytics
Table 31: Rest of World Current and Future Analysis for Bioresorbable Scaffolds Market Analyzed with Annual Sales in US$ Thousands for Years 2016 through 2024 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 17 (including Divisions/Subsidiaries 18)

  • The United States (6)
  • Japan (1)
  • Europe (5)
    • France (1)
    • Germany (2)
    • The United Kingdom (1)
    • Rest of Europe (1)
  • Asia-Pacific (Excluding Japan) (6)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Abbott Laboratories (USA)
  • Amaranth Medical, Inc. (USA)
  • Arterial Remodeling Technologies SA (France)
  • BIOTRONIK SE & Co. KG (Germany)
  • Elixir Medical Corp. (USA)
  • Kyoto Medical Planning Co., Ltd. (Japan)
  • REVA Medical, Inc. (USA)
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll